Abzena and Argonaut Manufacturing Services, two CDMOs, formed a partnership to provide drug substance and drug product manufacturing solutions for biopharmaceutical organizations. This alliance offers a streamlined approach for customers looking to rapidly progress therapies into the clinic, or onward into later-stage commercial manufacturing, according to Matt Stober, CEO of Abzena.

The partnership uses a single development and manufacturing team to transition from early discovery services (ranging from antibody engineering, developability, formulation development, cell line development, process, and analytical development) through clinical and commercial manufacturing of drug substance and drug product, said Wayne Woodard, CEO of Argonaut.

By harmonizing Abzena’s capabilities in antibody discovery, development, and cGMP manufacturing with Argonaut’s sterile fill-finish offering, the companies create a full-spectrum service model designed to optimize efficiency and accelerate development timelines, pointed out Stober.

“Abzena’s mission is to rapidly move medicines forward to patients in need. Embarking on this strategic partnership with Argonaut further demonstrates our commitment to this mission, marking a significant milestone in our quest to provide streamlined solutions that address the unique needs of our customers,” he continued.

“For the past few years, Argonaut and Abzena have been successfully building and strengthening their partnership. Today, we further enhance this collaboration by publicly recognizing the value that our two companies can generate for our clients,” noted Woodard.

“Ecosystems are an integral part of our business, and these partnerships are crucial in providing comprehensive support to all our clients, regardless of their size, to ensure efficient and successful delivery of their drugs to patients.”

Previous articlePotential Sanfilippo Syndrome Treatment, Anakinra, Shows Promise in Clinical Trial
Next articleEndpoints: Considerations for Hit to Lead Selection of a Bispecific Antibody in Oncology